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In children with cryptogenic Lennox-Gastaut syndrome we found a functionally impaired humoral 
immune response to a primary antigen (haemocyanin), despite signs of a triggered immune system 
consisting of elevated IgG concentrations. This combination of immunological findings, considered to 
be the expression of a dysbalanced-triggered as well as functionally impaired-immune system, has also 
been described in an auto-immune disease like systemic lupus erythaematodes in humans, and in 
genetically epilepsy-prone rats. The interactions between the immune system and the nervous system in 
Lennox-Gastaut syndrome will be discussed.
Baziel G.M. van Engelen, MD, Department o f  Neurology, University Hospital Nijmegen, P.O. Box 91011 
6500 HB Nijmegen, The Netherlands
INTRODUCTION
The Lennox-Gastaut syndrome (LGS) is an unexplained, age- 
related epileptic encephalopathy with a tendency to become 
chronic [1]. Various pathophysiologic mechanisms have been 
suggested to explain this condition including the hypothesis 
that it results from an aberrant immune function. Indications 
supportive for this hypothesis include the reports on anti­
bodies to brain tissue [2,3], the suggested effect of intravenous 
immunoglobulin [4], and the reported associations with 
certain HLA class II alleles in patients with LGS [5]. The 
publications on humoral and cellular immunity are conflict­
ing, impaired immunity (predominantly IgG2 and IgA defi­
ciencies) [6-8], normal immunity [9], and increased humoral 
or cellular immunity [7, 10] have been described. Indirect 
suggestive evidence for reciprocal interactions between the 
immune and nervous system in epilepsies are the immunolo­
gical alterations induced by proper anticonvulsant drugs like 
phenytoin and carbamazepine, and the anticonvulsant effect 
of immunosuppressive drugs like adrenocorticotropic hor­
mone and corticosteroids in otherwise intractable epilepsies 
(for review, [4]).
For the present study we attempted to select a relatively 
homogeneous group of cryptogenic LGS patients, and an 
epilepsy control group receiving the same anticonvulsants. In
addition to studies on humoral and cellular immunity, we 
measured the in vivo primary humoral immune response after 
subcutaneous injection of the neoantigen, a-Helix pomatia 
haemocyanin (HPH). The in vivo immune response is a 
sensitive test of total immune responsiveness [11,12] measur­
ing both the afferent as well as the efferent arc of the immune 
system, and it is a functional test which might be able to 
detect a possible modulating influence of the epileptic brain 
on immune responsiveness. The results in both epilepsy 
groups are compared with those of normal controls and a 
possible misregulation of the immune system in LGS is 
discussed in the light of the conflicting data in the literature.
MATERIALS AND M ETHODS
Patients. The study population consisted o f 12 children (four girls, 
eight boys, m ean age 4.4 years) with cryptogenic LGS receiving 
valproate, either as m onotherapy or in combination, with other 
anticonvulsants, especially nitrazepam. An age and sex matched 
epilepsy control group consisted o f seven children with other types 
o f  epilepsy [13] (situation-related seizures («=1), symptomatic 
generalized seizures (« =  4), temporal lobe epilepsy [n — 2)) receiving 
the same regimen of anticonvulsant drugs as the LGS group. The 
normal control group was derived from a previously published 
reference group consisting of 114 healthy children aged 1 month to
16 years [14]. The study protocol was reviewed and approved by the
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institutional ethical review board of our hospital. Informed consent 
was obtained from the children’s parents.
LGS was defined by the characteristic triad: (1) multiple epileptic 
seizure types (axial tonic, atypical absences, atonic seizures) possibly 
associated with generalized tonic-clonic seizures and partial seizures; 
(2) inter-ictal slow spike-waves (fewer than three per second) in 
awake electroencephalography (EEG); (3) mental retardation or 
deterioration with personality disorders, with onset between 1 and
5 years of age [1]. Cryptogenic aetiology was defined as epilepsy of 
unknown cause in infants or children with unremarkable neuro­
mental development prior to onset of seizures; normal physical 
examination; no abnormalities on cerebral CT or M R  imaging, 
except for a slight dilatation of ventricles; no known mental 
retardation syndromes, chromosomopathy, or inborn errors of 
metabolism.
Immunological studies. Serum total IgG, IgA and IgM concentra­
tions were determined as described earlier [14]. Serum IgG subclass 
concentrations were determined by radial immunodiffusion, and 
calibrated against standard serum containing 6.2 g/1 IgGj; 2.4 g/1 
IgG2; 0.64 g/1 IgG3; and 0.46 g/1 IgG4 ( H 0 0 “020, CLB, Amsterdam, 
The Netherlands). Pre-immunization anti-HPH titres were deter­
mined with an indirect ELISA technique and expressed as percentage 
of positive reference samples [12], Afterwards, 1 ml (1 mg) of HPH 
was given subcutaneously and serum was obtained 2 weeks (in LGS 
patients also 4) and 6 weeks after immunization. H PH  is a well 
characterized, easily available primary immunogen, whose safety has 
been documented [11,12]. One subcutaneous injection of 1 mL elicits 
a strong primary humoral (IgG, IgA, IgM) and cellular immune 
response in normal volunteers. Percentages of B cells were deter­
mined by immunofluorescence microscopy using anti-human immu­
noglobulin antisera (Kallestad Lab. Inc., Austin, TX, USA). The 
percentages of CD 3, CD4, and CD8 positive T  cells were determined 
using monoclonal antibodies (OKT3, OKT4, OKT8, respectively; 
Coulter Co., Hialeah, FL, USA). Lymphocyte proliferation in vitro 
after stimulation by phytohaemagglutinin and pokeweed mitogen 
was studied by standard methods.
All immunological studies were performed at a time when neither 
the patients nor controls showed any clinical signs of intercurrent 
infection.
Statistical analyses. The results of the immunological investiga­
tions in the LGS group and the epilepsy control group were 
compared with each other and also with the normal control group. 
Concentrations of immunoglobulins and subclasses were corrected 
for age by subtracting the expected value as calculated from the data 
of the reference group [14] from the actual value found. Anti-HPH 
titres measured in the LGS group and the epilepsy control group, 
were compared with those of previously described normal control 
children [15]. All group differences were evaluated using the Kruskal- 
Wallis test. In addition, Spearman’s rank correlation coefficients 
were determined between IgG, IgA and IgM concentrations, and 
their respective anti-HPH titres. Significance was set a t P  = 0.05 
(two-sided). In the case of multiple testing, the Bonferroni correction 
was used.
RESULTS
The only significant difference between the LGS group and 
the normal control group is an increased concentration of 
total IgG in the LGS group (P < 0.05). The epilepsy control
group did not show significantly increased IgG concentra­
tions compared with normal controls, whereas the difference 
between the epilepsy control group and the LGS group was 
not significant. IgGi, IgG2 and IgG3 concentrations did not 
differ significantly between the LGS group and any of the 
control groups.
The LGS group did not differ from any of the control 
groups with regard to percentage of B cells (mean 11.3%, 
standard deviation (SD) 5.5; individual values: 15,14,10,17,
5, 21, 8, 14, 7, 6, 3, and 15%), CD3 positive cells (mean 
64.5%, SD 6.4; individual values: 66,73,65,72, 70, 60,60,60, 
70, 65, 61, and 52%) or CD4/CD8 ratio (mean 2.8, SD 0.9; 
individual values: 1.8, 5.2, 2.9, 2.8, 2.4, 2.1, 2.3, 2.1, 2.3, 3.1,
3.1, and 3.1). Proliferation of peripheral blood lymphocytes 
to phytohaemagglutinin and pokeweed mitogen was normal 
in both the LGS and the epilepsy control groups.
Antibody responses to haemocyanin immunization
All pre-immunization anti-HPH titres were negative except 
for some very low IgG and IgM titres in all three groups 
(Fig. 1). The peak IgM response after 2 weeks did show 
significant differences between the groups (P<0.01): it was 
decreased in the LGS group compared with the epilepsy 
control group (P < 0.05) and to the normal controls 
(P<0 .005), whereas the epilepsy control group and the 
normal controls did not differ. The IgA response after 2 
weeks was significantly different in the three groups 
(P<0.05) and was reduced in both the LGS (P<  0.05) and 
the epilepsy control group (jP<0.05) compared to normal 
controls, whereas the two epilepsy groups did not differ from 
each other. The IgG response did not differ significantly 
between the three groups (P>0.05), although there was a 
trend towards lower IgG responses in the LGS group 
compared with normal controls (P = 0.04). Concerning the 
kinetics of the response, the increase in IgG, IgA and IgM 
anti-HPH titres, respectively between 0 and 2 weeks, showed 
the same differences as the peak anti-HPH titres after 2 weeks. 
The decline in all three classes of anti-HPH titres between 2 
and 6 weeks was the same for all three groups.
In the LGS group there was a significantly positive 
correlation between IgM and anti-HPH IgM, anti-HPH 
IgA and anti-HPH IgG concentrations, respectively (all 
P<0.05). The Spearman’s rank correlation coefficients were
0.65, 0.75 and 0.66, respectively. No such significant corre­
lation existed between the serum IgG and IgA concentrations, 
and their anti-HPH titres (all P>0.05).
DISCUSSION
The main finding of this study is the impaired humoral 
immune response in patients with cryptogenic LGS. Until 
now, this has not been reported in LGS nor in other types of 
epilepsy. A decreased cellular immune response after dinitro- 
chlorobenzene sensitization has only been described in one
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Fig. 1. In vivo IgG, IgA and IgM primary immune responses to haemocyanin (as percentage of positive reference samples) in the LGS 
group (in— 12), epilepsy control group { n ~ l ), and in normal controls {n — 8).
report on a group of patients with cryptogenic as well as 
symptomatic types of LGS and West syndrome [8]. Factors 
underlying the impaired humoral immune response in LGS 
patients are not yet known, and some can be ruled out from
the present study. The immune response does not have a 
delayed time course (anti-HPH titres declined between 2 and
4 weeks); there is no decrease in the number of different types 
of immune cells; no decrease in IgM concentration (IgM
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enhances the humoral immune response [16]); and no defect 
in lymphocyte proliferation in vitro. Since HPH is a T cell 
dependent antigen the impaired humoral immune response 
does not necessarily point to a primary B cell defect. A 
disturbance in the afferent arc of the immune system, a 
defective antigen processing or presentation by macrophages 
or a deficient interaction between B and T cells, may well 
account for the decreased immune responsiveness.
In addition (unexpected in the light of the impaired 
immune responses), the increased total IgG concentration 
in the LGS group points to a triggered immune system. This 
increase in total IgG in epilepsy has also been reported by 
others [7] and by our previous study [14] on a more extended 
epilepsy group consisting of the present LGS patients and 
patients with West syndrome. Such a triggered immune 
system can be caused by infectious or autoimmune processes 
[17], Infectious causes have been excluded during the inves­
tigation period in our study.
In the current study, a drug effect cannot be entirely ruled 
out, but seems unlikely because both the LGS group and the 
epilepsy control group received the same anticonvulsants. 
Moreover, valproate and nitrazepam were used, drugs that 
are not known to have an effect on immunoglobulins.
A triggered as well as functionally impaired immune 
system, which may be called a dysbalanced immune system, 
is in accordance with and may partly explain the conflicting 
literature on immunological investigations in epilepsy. A 
study showing an elevated B cell number has been inter­
preted as conflicting with the report on an impaired cellular 
immune responsiveness [8, 10]. Because we have measured 
both, we have been able to reproduce in LGS patients just this 
combination of a triggered but nevertheless functionally 
impaired immune system, which has also been described in 
an autoimmune disease like systemic lupus erythaematodes in 
humans [12], and in genetically epilepsy-prone rats [17]. 
Therefore, we think that this combination of findings, 
instead of being the expression of conflicting results, may 
have a biological significance pointing to a misregulation of 
the immune system. A possible explanation may be that high 
IgG concentrations cause a feedback inhibition of the 
immune response leading to a diminished capacity to 
respond to new antigenic challenges [16, 17]. Nevertheless, 
we could not confirm a significant negative correlation 
between IgG concentrations and immune responses in the 
LGS group. In addition, also the epilepsy control group 
showed increased IgG concentrations, however, without 
impaired humoral immune responses. We did find a signifi­
cant positive correlation in the LGS group between IgM 
concentrations and immune responses, which is in accor­
dance with the reported enhancing effect of IgM antibodies 
on the humoral immune response [16].
In conclusion, the present study found indications not of an 
immune deficiency, but rather of an immune dysbalance or 
misregulation in LGS. Interestingly, LGS a severe form of 
epilepsy, can be defined neurologically also as a dysbalance,
in this case of excitation and inhibition in neural networks 
leading to functional disturbances [18]. There are several 
possibilities that may account for the association between 
an immune and neural dysbalance [19]. One possibility is that 
the dysbalanced immune system alters neural function 
[20-22] and causes epilepsy. Certain antibodies intracere- 
brally injected in experimental animals induce epileptiform 
activity (for review [23]). Secondly, the neural dysbalance
i.e., epilepsy may modify immune function [24]. As a con­
sequence of epilepsy central nervous system (CNS) antigens 
may become exposed to and trigger the immune system. In 
experimental animals, lesions of the anterior hypothalamus 
modify asthma and reduce humoral and cellular responses to 
foreign antigens [25], Thirdly, the disturbances both in the 
immune and nervous system could be due to a common 
underlying biological process. This has been described in 
experimental mice that develop severe autoimmune disease 
and learning disabilities, each of which possibly originate 
from neuropathological anomalies consisting of ectopic 
collections of neurons [26]. Whatever the exact interaction 
might be, one could speculate that the association between 
the neural dysbalance and the immune dysbalance in LGS 
may offer the potential of new treatment approaches in this 
type of intractable epilepsy by addressing the nervous system 
via the immune system,
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